Tweedy Browne Co LLC Has $816,000 Position in Haleon plc (NYSE:HLN)

Tweedy Browne Co LLC trimmed its position in Haleon plc (NYSE:HLN) by 8.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 85,509 shares of the company’s stock after selling 8,075 shares during the period. Tweedy Browne Co LLC’s holdings in Haleon were worth $816,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Thrivent Financial for Lutherans raised its holdings in Haleon by 69.0% in the third quarter. Thrivent Financial for Lutherans now owns 55,593 shares of the company’s stock worth $588,000 after purchasing an additional 22,701 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Haleon by 41.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,583 shares of the company’s stock valued at $2,154,000 after buying an additional 59,719 shares in the last quarter. Aureus Asset Management LLC raised its stake in Haleon by 18.3% during the 3rd quarter. Aureus Asset Management LLC now owns 14,881 shares of the company’s stock worth $157,000 after buying an additional 2,298 shares during the period. Benjamin Edwards Inc. bought a new position in Haleon during the third quarter worth about $805,000. Finally, Hilltop Holdings Inc. acquired a new position in Haleon in the third quarter valued at about $133,000. Institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HLN shares. HSBC reiterated a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Six investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.95.

Haleon Stock Performance

Shares of HLN opened at $10.28 on Tuesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12 month low of $7.99 and a 12 month high of $10.80. The firm has a fifty day simple moving average of $9.96 and a 200 day simple moving average of $9.87. The stock has a market capitalization of $46.52 billion, a price-to-earnings ratio of 30.22, a PEG ratio of 2.82 and a beta of 0.25.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. Research analysts forecast that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. This is a positive change from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. This represents a dividend yield of 1.6%. Haleon’s payout ratio is 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.